Medical Tech Stock Aethlon Medical, Inc. (NASDAQ: AEMD) Gains On News

(MENAFN- Investor Ideas) March 12, 2026 – (Investorideas Newswire) Reports Breaking Medical Tech Stock news -Aethlon Medical, Inc. (Nasdaq: AEMD ), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.

The stock gained today on news, currently trading at 1.7300+0.0794 (+4.81%), with a day's high of $1.94 on a volume of over 859,000 shares as of this report.

Aethlon Medical, Inc. (Nasdaq: AEMD ) today announced that it is evaluating a range of strategic opportunities and has engaged Maxim Group LLC (“Maxim”) to act as the company's exclusive financial advisor in connection with this process.

The Company engaged Maxim following preliminary inbound interest regarding potential strategic opportunities. Maxim will assist the Company in reviewing a range of potential transactions, including partnerships, mergers, acquisitions, or other opportunities involving the Company.

James Frakes, Chief Executive Officer and Chief Financial Officer of Aethlon, stated,“The company continues to execute its development activities, having completed the second cohort of our Australian oncology trial. Safety data from that cohort will be submitted to the independent Data Safety Monitoring Board for review. At the same time, we are evaluating strategic alternatives with the assistance of Maxim as part of our ongoing efforts to assess opportunities available to the Company and its shareholders.”

The company has not established a definitive timeline for this evaluation and can provide no assurance that any transaction will result from this process. The Company will pursue only those opportunities that the Board believes are appropriate for the Company and its shareholders.

About Maxim Group LLC

Founded in 2002, Maxim Group is a leading full-service investment bank, securities, and wealth management firm headquartered in Midtown Manhattan, providing a comprehensive array of financial services, including investment banking, global institutional sales, equity research, fixed income and derivative sales & trading, merchant capital, private wealth management, and prime brokerage services to a diverse range of corporate clients, institutional investors, and high-net-worth individuals. Maxim Group is a registered broker-dealer with the U.S. Securities and Exchange Commission and the Municipal Securities Rulemaking Board (MSRB). To learn more about Maxim Group, visit

About Aethlon Medical, Inc.

Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical-stage medical device company headquartered in San Diego, California. Aethlon is advancing the Hemopurifier, to address unmet needs in oncology and infectious disease, using a novel platform designed to selectively remove circulation pathogenic targets from biologic fluids.

For more information, visit and follow the Company on LinkedIn.

About Aethlon and the Hemopurifier®

Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful EVs from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where EVs may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which EVs have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

Additional information can be found at.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Risks and uncertainties include, but are not limited to, clinical trial outcomes, regulatory approvals, the ability to obtain additional financing, and market acceptance of the Company's products, as more fully described in the Company's filings with the Securities and Exchange Commission. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

Company Contact:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
...

Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
...

Aethlon Medical Inc. (Nasdaq:AEMD) is a featured biotech stock on Investorideas More info on AEMD at Investorideas Visit: /CO/AEMD/

Get News Alerts on Aethlon Medical

Get more biotech and medical tech news, articles, podcasts and stock directories

About Investorideas - Big Investing Ideas

Investorideas is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all

Follow us on X @investorideas

Follow us on Facebook

Follow us on YouTube

Sign up for free stock news alerts at Investorideas

/Resources/Newsletter

MENAFN13032026000142011025ID1110858774